KR20230107275A - 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물 - Google Patents

비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물 Download PDF

Info

Publication number
KR20230107275A
KR20230107275A KR1020237018777A KR20237018777A KR20230107275A KR 20230107275 A KR20230107275 A KR 20230107275A KR 1020237018777 A KR1020237018777 A KR 1020237018777A KR 20237018777 A KR20237018777 A KR 20237018777A KR 20230107275 A KR20230107275 A KR 20230107275A
Authority
KR
South Korea
Prior art keywords
bedaquiline
week
combination
administered
clarithromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237018777A
Other languages
English (en)
Korean (ko)
Inventor
켄 쿠로사와
시비 마하데반
크리스핀 캄빌리
타다이시 코
스테판 루이스 에프 로쎄누
워터 마르타 엠 윌렘스
제이케 엘리스 바이웬가
에티엔 길버트 알랜 에르널트
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20230107275A publication Critical patent/KR20230107275A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237018777A 2020-11-12 2021-11-10 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물 Pending KR20230107275A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063113149P 2020-11-12 2020-11-12
US63/113,149 2020-11-12
PCT/EP2021/081193 WO2022101244A1 (en) 2020-11-12 2021-11-10 Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases

Publications (1)

Publication Number Publication Date
KR20230107275A true KR20230107275A (ko) 2023-07-14

Family

ID=78695693

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018777A Pending KR20230107275A (ko) 2020-11-12 2021-11-10 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물

Country Status (7)

Country Link
US (1) US20230346770A1 (https=)
EP (1) EP4243800A1 (https=)
JP (1) JP2023549605A (https=)
KR (1) KR20230107275A (https=)
CN (1) CN116406270A (https=)
TW (1) TW202233168A (https=)
WO (1) WO2022101244A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250169098A (ko) 2024-05-24 2025-12-02 주식회사 에이엔제이사이언스 티오펩타이드 화합물을 포함하는 비결핵 항산균 감염증의 예방, 개선 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1527050T3 (da) 2002-07-25 2010-07-19 Janssen Pharmaceutica Nv Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
AU2005249231B2 (en) 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
UA97813C2 (uk) 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
LT3250182T (lt) * 2015-01-27 2023-07-10 Janssen Pharmaceutica Nv Dispersinės kompozicijos
JOP20200004B1 (ar) * 2017-07-14 2023-09-17 Janssen Pharmaceutica Nv تركيبات طويلة المفعول
WO2020144197A1 (en) * 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases

Also Published As

Publication number Publication date
WO2022101244A1 (en) 2022-05-19
JP2023549605A (ja) 2023-11-28
CN116406270A (zh) 2023-07-07
US20230346770A1 (en) 2023-11-02
EP4243800A1 (en) 2023-09-20
TW202233168A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
Kobashi et al. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease
US7928115B2 (en) Methods of treating travelers diarrhea and hepatic encephalopathy
Tapson et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial
Bailo et al. Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development
Hoover et al. Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers
JP2025081386A (ja) 非結核性抗酸菌症の処置における組合せ
RU2540513C2 (ru) Способы лечения печеночной энцефалопатии
Calcagno et al. Drugs for treating infections caused by non-tubercular mycobacteria: A narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine
Janssen et al. Telacebec, a potent agent in the fight against tuberculosis: findings from a randomized, phase 2 clinical trial and beyond
US20200253959A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
KR20230107275A (ko) 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
Golia et al. Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease
HK40096376A (zh) 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
Snell The treatment of tuberculosis: current status and future prospects
US11590154B2 (en) Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
HK40050798A (en) Combination in the treatment of nontuberculous mycobacterial diseases
CN119564683B (zh) 一种抗分枝杆菌感染的联合增效药物组合物
US20250228828A1 (en) Methods of treating hepatic encephalopathy
EP4444725A1 (en) Non-tuberculosis mycobacteria infection treatment
Alan et al. Rifampicin (Rifampin)
Maesen et al. Pulse dosing with bacampicillin in treatment of acute exacerbations of chronic bronchitis
Brown et al. Antimicrobial agents: bacterial/fungal
Mans et al. Phase I Study of Three-Times Daily Oral Etoposide in Patients with Refractory Solid Tumours.
Prescott Antiinfective Drugs: Declining R&D? Clinical Updates

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902